<div id="readability-page-1"><p>Shares of Alvotech (NASDAQ:ALVO - Get Free Report) have received an average recommendation of &#34;Hold&#34; from the six analysts that are currently  covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, two have assigned  a hold rating and two have issued  a buy rating on  the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $8.60.</p><ul><li>Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem</li></ul><p>Several analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft  reiterated a &#34;hold&#34; rating and issued a $8.00 target price (down previously from $14.00) on shares of Alvotech in a research report on Tuesday, November 4th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Alvotech in a research note on Wednesday, October 8th. Wall Street Zen cut Alvotech from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 22nd. Morgan Stanley  set a $10.00 price target on Alvotech in a research note on Wednesday, December 3rd. Finally, Northland Securities  set a $10.00 target price on shares of Alvotech in a research report on Tuesday, November 4th.</p><p><b>Read Our Latest Analysis on Alvotech</b></p><h2>Institutional Inflows and Outflows</h2><ul><li>2 Generic Drug Makers With Growing Runways</li></ul><p>Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wyoming acquired a new stake in shares of  Alvotech in the third quarter valued at approximately $54,000.  Magnetar Financial LLC acquired a new stake in shares of  Alvotech in the 3rd quarter worth $86,000.  ProShare Advisors LLC purchased a new position in shares of  Alvotech during the 3rd quarter worth $91,000.  Ulland Investment Advisors LLC acquired a new position in shares of  Alvotech during the 3rd quarter valued at about $92,000.  Finally, Orion Porfolio Solutions LLC purchased a new stake in shares of  Alvotech in the third quarter valued at about $92,000. </p><h2>Alvotech Price Performance</h2><p>Alvotech stock opened at $4.64 on Friday. The stock has a market capitalization of $1.40 billion, a PE ratio of 20.17 and a beta of 0.11. The business has a 50 day simple moving average of $5.14 and a 200-day simple moving average of $7.33. Alvotech has a 12 month low of $4.32 and a 12 month high of $13.70. </p><p>Alvotech (NASDAQ:ALVO - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.07). The business had revenue of $113.95 million for the quarter, compared to analysts' expectations of $116.80 million. Alvotech had a net margin of 12.12% and a negative return on equity of 26.10%.  On average, equities research analysts anticipate that  Alvotech will post -0.07 EPS for the current fiscal year. </p><h2>Alvotech Company Profile</h2> (Get Free Report)<p>Alvotech <span>NASDAQ: ALVO<span></span></span> is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.  </p><p>Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).</p><h2>See Also</h2><ul><li>Five stocks we like better than Alvotech</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li><li>First Time Since 2007: All Warnings Active</li><li>How the Rich Retire</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxWTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxWTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alvotech Right Now?</h2><p>Before you consider Alvotech, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alvotech wasn't on the list.</p><p>While Alvotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALVO

<p>Alvotech (NASDAQ:ALVO) has received a consensus recommendation of "Hold" from six analysts. Two analysts rated it as a sell, two as hold, and two as buy. The average 12-month target price is $8.60. Recent reports include Deutsche Bank's hold rating with a target of $8.00, and Morgan Stanley's target of $10.00. Alvotech's stock opened at $4.64, with a market cap of $1.40 billion. The company reported a loss of $0.02 EPS for the last quarter, missing estimates. Alvotech specializes in biosimilar medicines, targeting established biologic therapies.</p>

Alvotech (NASDAQ:ALVO) Receives Consensus Recommendation of "Hold" from Analysts